Kim SB, Dent R, Wongchenko MJ, Singel SM, Baselga J; LOTUS investigators. Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS. Lancet Oncol 2017; 18: e638—In the Declaration of interests section of this Correspondence, Jose Baselga’s declarations should read “JB reports non-financial support from Roche/Genentech during the conduct of the study; personal fees and stock from Aura Biosciences, Northern Biologics (f/k/a Mosaic Biomedicals), Infinity Pharmaceuticals, PMV Pharma, Juno Therapeutics, TANGO (f/k/a Synthetic Lethal), GRAIL, Varian Medical Systems and Seragon; stock from ApoGen Biotechnologies and Foghorn Therapeutics; personal fees and non-financial support from Novartis and Eli Lilly; and non-financial support from Daiichi Sankyo and Bristol Myers Squibb, outside the submitted work”.
[Corrections] Correction to Lancet Oncol 2017; 18: e638
Leggi l'articolo originale